Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.7600 (-13.51%) ($5.7600 - $5.7600) on Tue. Feb. 2, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.45% (three month average) | RSI | 69 | Latest Price | $5.7600(-13.51%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.7% a day on average for past five trading days. | Weekly Trend | ADMS advances 14.6% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) UNG(24%) SIL(20%) SLV(17%) XRT(17%) TLT(16%) | Factors Impacting ADMS price | ADMS will decline at least -2.225% in a week (0% probabilities). JETS(-25%) XLE(-20%) EWP(-16%) XLB(-15%) XOP(-14%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.225% (StdDev 4.45%) | Hourly BBV | -0 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $5.85(-1.54%) | 10 Day Moving Average | $5.4(6.67%) | 20 Day Moving Average | $5.01(14.97%) | To recent high | -13.5% | To recent low | 15.2% | Market Cap | $163m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |